Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.' - 2Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- 3Manual for extravagance SUVs for seniors
- 4Israel says Iran's military industry will be destroyed 'within days'
- 56 Tire Brands Reasonable for Seniors
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- The Main 15 Powerful Business Heads of Today
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Instructions to Discuss Successfully with Your Auto Collision Lawyer
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- AfD in Brandenburg takes back suit against the intelligence service
- Great DSLR Cameras for Photography Devotees
- Treasure trove found in Egyptian tomb solves ancient mystery
